Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5642612 | 0.85 | F10 (0.70) | F10KCNH2KLKB1 | |
| SCHEMBL5642276 | 0.84 | F10 (0.66) | F10KCNH2KLKB1 | |
| SCHEMBL5644186 | 0.83 | F10 (0.74) | F10KCNH2KLKB1 | |
| SCHEMBL2433664 | 0.83 | F10 (0.78) | F10KCNH2KLKB1 | |
| SCHEMBL5388278 | 0.82 | F10 (0.74) | F10KCNH2KLKB1 | |
| SCHEMBL6109799 | 0.82 | PPARG (0.63) | F10KCNH2KLKB1 | |
| SCHEMBL5647384 | 0.82 | F10 (0.68) | F10KCNH2KLKB1 | |
| SCHEMBL890676 | 0.82 | F10 (0.74) | F10KCNH2KLKB1 | |
| SCHEMBL6111211 | 0.81 | F10 (0.74) | F10KCNH2KLKB1 | |
| SCHEMBL10179257 | 0.81 | F10 (0.76) | F10KCNH2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227492-B2 | Sulfoxamine derivatives as factor Xa inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2012-07-24 | — | — | US | claimed |
| US-20110065717-A1 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2011-03-17 | — | — | US | claimed |
| EP-2188257-A2 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | Cadila Healthcare Limited (IN) | 2010-05-26 | — | — | EP | claimed |
| WO-2009053999-A2 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2009-04-30 | — | — | WO | claimed |
| US-8227492-B2 | Sulfoxamine derivatives as factor Xa inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| EP-2188257-A2 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | Cadila Healthcare Limited (IN) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009053999-A2 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065717-A1 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F12, F2 | F10 8/4885KCNH2 4530/4885KLKB1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.